Joseph Thome
Stock Analyst at TD Cowen
(0.39)
# 4,121
Out of 4,944 analysts
17
Total ratings
28.57%
Success rate
-22.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Thome
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DRUG Bright Minds Biosciences | Initiates: Buy | n/a | $40.30 | - | 1 | May 13, 2025 | |
| VRDN Viridian Therapeutics | Initiates: Buy | n/a | $18.86 | - | 1 | Nov 25, 2024 | |
| UTHR United Therapeutics | Maintains: Buy | $350 → $400 | $309.72 | +29.15% | 2 | Oct 21, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | n/a | $15.62 | - | 1 | Jul 2, 2024 | |
| ALKS Alkermes | Initiates: Buy | $34 | $28.63 | +18.76% | 1 | Jun 17, 2024 | |
| PRME Prime Medicine | Initiates: Buy | n/a | $3.81 | - | 1 | Apr 8, 2024 | |
| MGX Metagenomi | Initiates: Outperform | n/a | $1.94 | - | 1 | Mar 5, 2024 | |
| PTCT PTC Therapeutics | Maintains: Market Perform | $32 → $30 | $48.17 | -37.72% | 2 | Mar 1, 2024 | |
| YMAB Y-mAbs Therapeutics | Downgrades: Market Perform | n/a | $8.51 | - | 1 | Jan 5, 2023 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | n/a | $37.67 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.31 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $130 | $109.39 | +18.84% | 2 | Jun 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $11.00 | - | 1 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.32 | - | 1 | Nov 23, 2021 |
Bright Minds Biosciences
May 13, 2025
Initiates: Buy
Price Target: n/a
Current: $40.30
Upside: -
Viridian Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: n/a
Current: $18.86
Upside: -
United Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $350 → $400
Current: $309.72
Upside: +29.15%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: n/a
Current: $15.62
Upside: -
Alkermes
Jun 17, 2024
Initiates: Buy
Price Target: $34
Current: $28.63
Upside: +18.76%
Prime Medicine
Apr 8, 2024
Initiates: Buy
Price Target: n/a
Current: $3.81
Upside: -
Metagenomi
Mar 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.94
Upside: -
PTC Therapeutics
Mar 1, 2024
Maintains: Market Perform
Price Target: $32 → $30
Current: $48.17
Upside: -37.72%
Y-mAbs Therapeutics
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $8.51
Upside: -
Xenon Pharmaceuticals
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $37.67
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.31
Upside: -
Jun 29, 2022
Maintains: Outperform
Price Target: $120 → $130
Current: $109.39
Upside: +18.84%
Jan 31, 2022
Initiates: Outperform
Price Target: n/a
Current: $11.00
Upside: -
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.32
Upside: -